ClinicalTrials.gg

Program

HJB647

A development code. Also written as “HJB647 low dose” and “HJB647 high dose”.

Its studies are mostly in Heart Failure · Hypertension, led by Novartis.

Furthest: phase 1, since Mar 6, 20262 company-led studies, 2 open or runningNext primary completion: Dec 8, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis22 open or runningphase 1since Mar 6, 2026Mar 6, 2026Dec 8, 2026phase 1 · NCT07465653
  • Named in Novartis’s own pipeline as HJB647, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 6, 2026First study: phase 1 study in Heart FailureFirst studyNCT07465653 · 12 planned · United States, Canada
  2. Jun 8, 2026Phase 1 study in HypertensionNCT07644364 · 64 planned · Japan

Ahead

  1. Dec 8, 2026Primary completion: phase 1 study in Heart FailureNCT07465653
  2. Dec 25, 2026Primary completion: phase 1 study in HypertensionNCT07644364

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07644364Hypertension · Japan1RecruitingDec 25, 202664
NCT07465653Heart Failure · United States, Canada1RecruitingDec 8, 202612

How it is read

Names in the registry

  • “HJB647 low dose”, 1 entry
  • “HJB647 high dose”, 1 entry
  • “HJB647”, 1 entry

Codes read as this program: HJB647.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.